Data investigation

Who Was Actually in the Trials

Every result comes with an unstated question: does it apply to you? A review of 246 trials and 139,566 participants shows who was studied, and the mismatch has a consistent shape.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·2 citations

Every result on this register comes with an unstated question: does it apply to you? A systematic review answered it directly, examining the baseline characteristics of 246 randomized trials covering 139,566 participants across twelve obesity medications and three decades.[1] The people studied are not the people affected, and the mismatch has a consistent shape.

Who was over-recruited, and who was missing

Baseline demographics across trials of orlistat, naltrexone–bupropion, phentermine–topiramate, liraglutide, semaglutide, lorcaserin, sibutramine, rimonabant, taranabant, tirzepatide, retatrutide and orforglipron, 1999–2023.[1]
Over-recruitedUnder-recruited
White participantsNon-White participants
Female participantsMale participants
Aged 40 or overOlder participants
Class 1 obesity (BMI 30.0–34.9) and class 2 (35.0–39.9)Class 3 obesity (BMI 40 or above)
The people with the most severe obesity are the least represented in the evidence for treating it.

That last row deserves the most attention, because it is backwards. People with class 3 obesity have the most to gain from an effective treatment, are the most likely to be prescribed one, and are the group a clinician is most confident about recommending it to. They are also the group the trials studied least.

What this does and does not mean

This review counted who enrolled. It did not show that under-represented groups respond differently. Those are separate questions, and treating them as one turns the finding into a claim the data cannot support. Nobody has shown that these drugs work less well for men, for older people or at higher BMI. Nobody can say either way, because the studies that would answer it were not designed to.

Uncertainty is not bad news, but it still matters. A confidence interval reported for a trial population applies to that population. Extending it to a group who made up a small fraction of participants is an act of judgment, usually a reasonable one, and always a step beyond what was measured. Some groups were hardly enrolled at all: for adults with a chronic spinal cord injury, the only semaglutide study we found followed five people.

There is one relevant piece of reassurance. Where a rare genetic subtype of obesity has been examined inside a trial, response was comparable to everyone else (see genetics caused it and the drug still worked). That is a different question from demographic representation, and it points the encouraging way.

A second check points the same encouraging way. Adults aged 40 or under are underrepresented in type 2 diabetes trials, so a post hoc analysis of the SUSTAIN and PIONEER programs went back and examined them separately. It found semaglutide reducing HbA1c and body weight across every age subgroup, particularly in young adults, with comparable rates of serious adverse events.[2]

That is the useful response to this problem: go back to the data and check, instead of assuming an underrepresented group responds the same or differently. Both times anyone has checked here, the answer has been reassuring, and so was a tirzepatide analysis of people whose obesity began before age 25.

Where this shows up in specific trials

Once you know the pattern, you will see it in almost every trial this register covers. These are not criticisms of individual studies; they are the same systematic skew, one paper at a time.

  • 82.4% women in the genome-wide study of who responds, which was also restricted to European ancestry (the genetics are real, and small).
  • 92% women, mean age 64 in the bone density study, which shapes everything it found (bone density and fracture risk).
  • 75% men, median age 68 in the peripheral artery disease trial. That is the opposite skew, for a condition that itself skews that way (how far you can walk).
  • 85% White in the retatrutide body composition substudy.
  • Chinese BMI thresholds and a mean age of 33 in a phase 2b trial whose results do not transfer straightforwardly (the drugs that are not here yet).

The BMI question has a second dimension the review does not address. Obesity is defined at a BMI of 25 rather than 30 in many Asian populations because risk rises at lower body mass. A trial recruiting at class 1 and class 2 by Western thresholds is therefore recruiting a different metabolic population than the same numbers would describe elsewhere. We cover that in the BMI threshold is not universal.

What to do with it

  • Check the baseline table, not just the result. Every trial publishes who was in it, and it takes ten seconds to see whether that includes people like you.
  • Treat effect sizes as estimates from a described population, which is what they are, rather than as universal constants.
  • Do not read under-representation as evidence of worse response. It is evidence of not knowing.
  • Expect this to improve slowly. The review’s own recommendation is that future trials recruit the groups they have been missing, which is the right conclusion and a slow one.

For what these numbers look like when applied outside a trial altogether, see what these drugs do outside a trial and who responds in the real world.

Frequently Asked Questions

Across 246 randomized trials and 139,566 participants over three decades, most trials over-recruited White, female participants aged 40 or over with class 1 and class 2 obesity, and under-recruited older participants, non-White participants, men, and people with class 3 obesity.
No. The review counted who enrolled, not how anyone responded. Nobody has shown a worse response. The studies capable of answering the question were not designed to.
Because people with a BMI of 40 or above have the most to gain from treatment and are the most likely to receive it, while being the group the trials studied least.
An effect size is an estimate from a described population. Applying it to someone who made up a small share of participants is a reasonable judgment, not a measurement.
In one case, yes and encouragingly. Participants in a large trial who carried mutations in the most common genetic cause of obesity lost weight comparably to everyone else. That is a different question from demographic representation, but it points the reassuring way.

References

  1. 1.Alsaqaaby MS, Cooney S, le Roux CW, Pournaras DJ. Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review The Lancet Diabetes & Endocrinology. 2024. PMID: 38723646.
  2. 2.Zaccardi F, Aroda VR, Arslan EG, et al. Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials Diabetes, Obesity and Metabolism. 2026. PMID: 41994903.

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list

8.8

altRX

Compounded semaglutide from $89/month at the same price at every dose

9.0

CoreAge Rx

Flat-priced compounded semaglutide at $79 a month, any dose

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →